Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies

Jason A. Koutcher, Alan A. Alfieri, Cornelia Matei, Kristen L. Meyer, James C. Street, Daniel S. Martin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

6-aminonicotinamide (6AN) has been shown to enhance radiosensitivity in vitro, although previous in vivo studies failed to show an effect. 31P NMR spectra were obtained by using a one-dimensional chemical shift imaging technique on a first generation transplant of the CD8FI spontaneous mammary carcinoma tumor model. Spectra were obtained both before and 10 h after treatment with 6AN (20 mg/kg). Changes in pH, nucleoside triphosphate/inorganic phosphate, and phosphocreatine/inorganic phosphate measured at 10 h post-6AN were not significant. A new beak was detected 10 h post-6AN, which was assigned to 6-phosphogluconate (6PG), indicating inhibition of the pentose phosphate pathway (PPP). Based on the spectral data demonstrating inhibition of the PPP at 10 h post-6AN, tumor-bearing mice were irradiated (15 Gy x 3 fractions) on Days 1, 10 or 11, and 21 10 h after administration of 6-aminonicotinamide (20 mg/kg). Tumor-bearing mice receiving 6AN alone (20 mg/kg x 3), radiation alone (15 Gy x 3), or saline were also studied. Tumor growth delay studies indicated that 6AN alone induced a small but significant tumor growth delay (4.3 ± 0.8 days). Radiation alone induced a tumor growth delay of 34.5 ± 2.7 days. Treatment with 6AN followed by radiation induced a tumor growth delay of 57.0 ± 3.8 days. This was significantly greater than the TGD values for treatment with 6AN alone or radiation (P < 0.01). No complete regressions were noted after treatment with 6AN or radiation alone. Concomitant therapy with 6AN plus radiation yielded 6/28 complete regressions (21%), which was significantly greater than radiation (P < 0.05) or 6AN alone (P < 0.01) on this mammary carcinoma.

Original languageEnglish (US)
Pages (from-to)887-892
Number of pages6
JournalMagnetic Resonance in Medicine
Volume36
Issue number6
StatePublished - Dec 1996
Externally publishedYes

Fingerprint

6-Aminonicotinamide
Pentose Phosphate Pathway
Growth
Neoplasms
Radiation
Breast Neoplasms
Phosphates
Beak
Phosphocreatine
Radiation Tolerance

Keywords

  • 6-aminonicotinamide
  • 6-phosphogluconate
  • NMR
  • pentose phosphate pathway

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Koutcher, J. A., Alfieri, A. A., Matei, C., Meyer, K. L., Street, J. C., & Martin, D. S. (1996). Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Magnetic Resonance in Medicine, 36(6), 887-892.

Effect of 6-aminonicotinamide on the pentose phosphate pathway : 31P NMR and tumor growth delay studies. / Koutcher, Jason A.; Alfieri, Alan A.; Matei, Cornelia; Meyer, Kristen L.; Street, James C.; Martin, Daniel S.

In: Magnetic Resonance in Medicine, Vol. 36, No. 6, 12.1996, p. 887-892.

Research output: Contribution to journalArticle

Koutcher, JA, Alfieri, AA, Matei, C, Meyer, KL, Street, JC & Martin, DS 1996, 'Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies', Magnetic Resonance in Medicine, vol. 36, no. 6, pp. 887-892.
Koutcher JA, Alfieri AA, Matei C, Meyer KL, Street JC, Martin DS. Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Magnetic Resonance in Medicine. 1996 Dec;36(6):887-892.
Koutcher, Jason A. ; Alfieri, Alan A. ; Matei, Cornelia ; Meyer, Kristen L. ; Street, James C. ; Martin, Daniel S. / Effect of 6-aminonicotinamide on the pentose phosphate pathway : 31P NMR and tumor growth delay studies. In: Magnetic Resonance in Medicine. 1996 ; Vol. 36, No. 6. pp. 887-892.
@article{1aea4ff31d404ca2b7dbdecdea4eef72,
title = "Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies",
abstract = "6-aminonicotinamide (6AN) has been shown to enhance radiosensitivity in vitro, although previous in vivo studies failed to show an effect. 31P NMR spectra were obtained by using a one-dimensional chemical shift imaging technique on a first generation transplant of the CD8FI spontaneous mammary carcinoma tumor model. Spectra were obtained both before and 10 h after treatment with 6AN (20 mg/kg). Changes in pH, nucleoside triphosphate/inorganic phosphate, and phosphocreatine/inorganic phosphate measured at 10 h post-6AN were not significant. A new beak was detected 10 h post-6AN, which was assigned to 6-phosphogluconate (6PG), indicating inhibition of the pentose phosphate pathway (PPP). Based on the spectral data demonstrating inhibition of the PPP at 10 h post-6AN, tumor-bearing mice were irradiated (15 Gy x 3 fractions) on Days 1, 10 or 11, and 21 10 h after administration of 6-aminonicotinamide (20 mg/kg). Tumor-bearing mice receiving 6AN alone (20 mg/kg x 3), radiation alone (15 Gy x 3), or saline were also studied. Tumor growth delay studies indicated that 6AN alone induced a small but significant tumor growth delay (4.3 ± 0.8 days). Radiation alone induced a tumor growth delay of 34.5 ± 2.7 days. Treatment with 6AN followed by radiation induced a tumor growth delay of 57.0 ± 3.8 days. This was significantly greater than the TGD values for treatment with 6AN alone or radiation (P < 0.01). No complete regressions were noted after treatment with 6AN or radiation alone. Concomitant therapy with 6AN plus radiation yielded 6/28 complete regressions (21{\%}), which was significantly greater than radiation (P < 0.05) or 6AN alone (P < 0.01) on this mammary carcinoma.",
keywords = "6-aminonicotinamide, 6-phosphogluconate, NMR, pentose phosphate pathway",
author = "Koutcher, {Jason A.} and Alfieri, {Alan A.} and Cornelia Matei and Meyer, {Kristen L.} and Street, {James C.} and Martin, {Daniel S.}",
year = "1996",
month = "12",
language = "English (US)",
volume = "36",
pages = "887--892",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of 6-aminonicotinamide on the pentose phosphate pathway

T2 - 31P NMR and tumor growth delay studies

AU - Koutcher, Jason A.

AU - Alfieri, Alan A.

AU - Matei, Cornelia

AU - Meyer, Kristen L.

AU - Street, James C.

AU - Martin, Daniel S.

PY - 1996/12

Y1 - 1996/12

N2 - 6-aminonicotinamide (6AN) has been shown to enhance radiosensitivity in vitro, although previous in vivo studies failed to show an effect. 31P NMR spectra were obtained by using a one-dimensional chemical shift imaging technique on a first generation transplant of the CD8FI spontaneous mammary carcinoma tumor model. Spectra were obtained both before and 10 h after treatment with 6AN (20 mg/kg). Changes in pH, nucleoside triphosphate/inorganic phosphate, and phosphocreatine/inorganic phosphate measured at 10 h post-6AN were not significant. A new beak was detected 10 h post-6AN, which was assigned to 6-phosphogluconate (6PG), indicating inhibition of the pentose phosphate pathway (PPP). Based on the spectral data demonstrating inhibition of the PPP at 10 h post-6AN, tumor-bearing mice were irradiated (15 Gy x 3 fractions) on Days 1, 10 or 11, and 21 10 h after administration of 6-aminonicotinamide (20 mg/kg). Tumor-bearing mice receiving 6AN alone (20 mg/kg x 3), radiation alone (15 Gy x 3), or saline were also studied. Tumor growth delay studies indicated that 6AN alone induced a small but significant tumor growth delay (4.3 ± 0.8 days). Radiation alone induced a tumor growth delay of 34.5 ± 2.7 days. Treatment with 6AN followed by radiation induced a tumor growth delay of 57.0 ± 3.8 days. This was significantly greater than the TGD values for treatment with 6AN alone or radiation (P < 0.01). No complete regressions were noted after treatment with 6AN or radiation alone. Concomitant therapy with 6AN plus radiation yielded 6/28 complete regressions (21%), which was significantly greater than radiation (P < 0.05) or 6AN alone (P < 0.01) on this mammary carcinoma.

AB - 6-aminonicotinamide (6AN) has been shown to enhance radiosensitivity in vitro, although previous in vivo studies failed to show an effect. 31P NMR spectra were obtained by using a one-dimensional chemical shift imaging technique on a first generation transplant of the CD8FI spontaneous mammary carcinoma tumor model. Spectra were obtained both before and 10 h after treatment with 6AN (20 mg/kg). Changes in pH, nucleoside triphosphate/inorganic phosphate, and phosphocreatine/inorganic phosphate measured at 10 h post-6AN were not significant. A new beak was detected 10 h post-6AN, which was assigned to 6-phosphogluconate (6PG), indicating inhibition of the pentose phosphate pathway (PPP). Based on the spectral data demonstrating inhibition of the PPP at 10 h post-6AN, tumor-bearing mice were irradiated (15 Gy x 3 fractions) on Days 1, 10 or 11, and 21 10 h after administration of 6-aminonicotinamide (20 mg/kg). Tumor-bearing mice receiving 6AN alone (20 mg/kg x 3), radiation alone (15 Gy x 3), or saline were also studied. Tumor growth delay studies indicated that 6AN alone induced a small but significant tumor growth delay (4.3 ± 0.8 days). Radiation alone induced a tumor growth delay of 34.5 ± 2.7 days. Treatment with 6AN followed by radiation induced a tumor growth delay of 57.0 ± 3.8 days. This was significantly greater than the TGD values for treatment with 6AN alone or radiation (P < 0.01). No complete regressions were noted after treatment with 6AN or radiation alone. Concomitant therapy with 6AN plus radiation yielded 6/28 complete regressions (21%), which was significantly greater than radiation (P < 0.05) or 6AN alone (P < 0.01) on this mammary carcinoma.

KW - 6-aminonicotinamide

KW - 6-phosphogluconate

KW - NMR

KW - pentose phosphate pathway

UR - http://www.scopus.com/inward/record.url?scp=0029950473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029950473&partnerID=8YFLogxK

M3 - Article

C2 - 8946354

AN - SCOPUS:0029950473

VL - 36

SP - 887

EP - 892

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

IS - 6

ER -